Patent Application
20240374564
The present invention relates to novel serotonin derivatives and their use as drugs, in particular for preventing and/or treating iron-associated disorders.
Iron is essential for biological processes, in particular for the conduct of erythropoiesis, the production process of red blood cells.
Many diseases have iron associated disorders related to an ineffective erythropoiesis. In particular, the disorders may relate to an overload of iron in the body. Among the most common iron overload-associated disorders are iron-loading associated anemias such as
β-thalassemia, myelodysplasia or hematopoietic stem-cell transplantation-related disorders.
β-thalassemia is a kind of genetic hemolytic anemia, related to an abnormal synthesis of β-hemoglobin, inducing apoptosis of erythroid progenitors. This disease affects 1.5% of the world's population, with a high prevalence in the poorest countries, in Africa and in India. It is responsible for 50 000 to 100 000 deaths per year. Current treatment consists in regular transfusions to maintain a normal hemoglobin level. However, repeated blood transfusions and hemoglobin apoptosis lead to an overload of iron in the organism causing high toxicity. It is thus essential to eliminate this excess of iron. Iron chelators, such as deferoxamine, may be used to this end and have been proved effective to reduce mortality. However, deferoxamine requires heavy treatment conditions such as daily injections and infusions. Oral iron chelators also exist such as deferiprone or deferasinox, for a more convenient use, but they are less effective. A new drug, Luspatercept, has been approved by FDA in 2019 for transfusion-dependent thalassemia. Luspatercept is a recombinant protein which has been shown to be effective in reducing anemia, decreasing transfusion requirements and lowering ferritin levels. However, the price of Luspatercept is particularly high, making it difficult to reach disadvantaged populations.
Myelodysplasia, or myelodysplastic syndrome (MDS), is a clonal hematopoietic disease characterized by anaemia related to an inefficient hematopoiesis and progression to acute myeloid leukemia. This syndrome mainly affects people aged 60 and over. As for β-thalassemia, blood transfusions help to maintain a normal hemoglobin level but lead to an overload of iron in the organism. This iron overload is also caused by the suppression of the production of hepcidin, a hormone regulating the iron metabolism in the body, due to this syndrome. Iron chelators are not recommended in view of their toxicity and the fragility of the patients. Luspatercept has also been recently approved for the treatment of this disease.
Approximately 40,000 allografts are performed each year in the world, including about 2,500 in France, with an estimated growth rate of 7% per year. An allograft refers to a transplant wherein the donor and the recipient are two separate individuals. Hematopoietic stem cell allograft is an evolving technique that offers the prospect of cure for hematologic malignancies (leukemias, lymphomas, myelomas) and other hematologic disorders (e.g., primary immune deficiency, bone marrow aplasia, myelodysplasia). Post-transfusion iron overload is relatively common in the context of hematopoietic stem cell transplantation. The use of iron chelators is very limited in post allograft treatment due to their toxicities. There is currently no alternative treatment to decrease post-transplant iron overload and help hematopoiesis so as to increase post-transplant survival.
There is therefore a need for alternative treatments of iron-associated disorders, in particular for preventing and/or treating the overload of iron observed for example in β-thalassemia, MSD or in post-transplant patients, obtainable at a reasonable cost and with a satisfactory safety and efficacy profile, at least similar to the one of Luspatercept used in β-thalassemia and MSD.
Serotonin, also called 5-hydroxytryptamine (5-HT), is a neurotransmitter responding to the following formula:
This molecule is essential for the metabolism, enabling to modulate mood, cognition, reward, learning, memory and numerous physiological processes such as vomiting and vasoconstriction. Serotonin is synthesized in neurons starting from tryptophan, an essential amino-acid brought to the brain through blood circulation. The rate limiting enzyme Tryptophan hydroxylase, responsible for serotonin synthesis is highly expressed in erythroid precursors and it has been shown that serotonin is synthesized at a critical transition checkpoint during erythroid progenitor's proliferation (Coman et al., Cell Reports, 2019, 26, 3246-3256). It has recently been demonstrated that the level of serotonin in the bone marrow directly impacts erythropoiesis. A high level of serotonin is able to enhance renewal of erythroid progenitors and thus to promote the production of red blood cells (Coman et la., Cell Reports, 2019). On the contrary, reduced levels of serotonin have been observed in patients suffering from myelodysplastic syndrome.
Without wishing to be bound by theory, the present inventors assume that serotonin is able to modulate erythropoiesis by influencing the iron availability needed for the production of red blood cells. Serotonin thus represents an interesting therapeutic target for the treatment of anaemia. However, serotonin has vasoconstriction/vasodilation properties via serotonin receptors, and thus cannot be injected.
To remedy the drawbacks of the existing treatments and based on the above hypothesis, the inventors have developed small serotonin derivatives, easy to prepare, and able to act as iron chelators to normalize iron stores and make iron available for vital biological processes, which do not exhibit the toxicity observed in current iron chelators.
In a first aspect, the present invention relates to compound of formula (I):
In a second aspect, the present invention relates to a compound of formula (I) for use as a drug.
According to a third aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) and at least one pharmaceutically acceptable excipient.
A fourth aspect of the present invention lies in a pharmaceutical composition comprising a compound of formula (I) and at least one pharmaceutically acceptable excipient for use as a drug.
For the purpose of the invention, the term “pharmaceutically acceptable” is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non-toxic, for a pharmaceutical use.
The term “pharmaceutically acceptable salt and/or solvate” is intended to mean, in the framework of the present invention, a salt and/or solvate of a compound which is pharmaceutically acceptable, as defined above, and which possesses the pharmacological activity of the corresponding compound.
The pharmaceutically acceptable salts comprise:
Acceptable solvates of the compounds of the present invention include conventional solvates such as those formed during the last step of the preparation of the compounds of the invention due to the presence of solvents. As an example, mention may be made of solvates due to the presence of water (these solvates are also called hydrates) or ethanol.
The term “halogen”, as used in the present invention, refers to a fluorine, bromine, chlorine or iodine atom.
The term “Cx-Cy alkyl”, as used in the present invention, refers to a straight or branched monovalent saturated hydrocarbon chain containing from x to y carbon atoms. Examples of C1-C24 alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
The term “Cx-Cy alkenyl”, as used in the present invention, refers to a straight or branched monovalent unsaturated hydrocarbon chain containing from x to y carbon atoms and comprising at least one double bond. Examples of C2-C24 alkenyl include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like.
The term “Cx-Cy alkynyl”, as used in the present invention, refers to a straight or branched monovalent unsaturated hydrocarbon chain containing from x to y carbon atoms and comprising at least one triple bond. Examples of C2-C24 alkynyl include, but are not limited to, ethynyl, propynyl (or propargyl), butynyl, pentynyl, hexynyl and the like.
The term “Cx-Cy haloalkyl” refers to a Cx-Cy alkyl chain as defined above wherein one or more hydrogen atoms are replaced by a halogen atom selected from fluorine, chlorine, bromine or iodine, preferably a fluorine atom. For example, it is a CF3 group.
The term “cycloalkyl” refers to a saturated, non-aromatic, hydrocarbon ring, typically comprising from 3 to 10, preferably 3 to 7 carbons and comprising one or more fused or bridged ring(s). Examples of C3-C10 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
The term “heterocycloalkyl” as used in the present invention refers to a non-aromatic, saturated or unsaturated monocycle or polycycle (comprising fused, bridged or spiro rings) comprising preferably 5 to 10, notably 5 or 6, atoms in the ring(s), in which the atoms of the ring(s) consist of carbon atoms and one or more, advantageously 1 to 4, and more advantageously 1 or 2, heteroatoms, such as a nitrogen, oxygen or sulphur atom, the remainder being carbon atoms. In particular, it can be an unsaturated ring, such as an unsaturated 5 or 6-membered monocycle. Preferably it comprises 1 or 2 nitrogen(s), in particular one. A heterocycle can be notably piperidinyl, piperizinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanyl, thiazolidinyl, isothiazolidinyl, oxazocanyl, thiazepanyl, benzimidazolonyl, 1,3-benzodioxole.
The term “aryl” refers to an aromatic hydrocarbon group preferably comprising from 6 to 12 carbon atoms and comprising one or more fused rings, such as, for example, a phenyl, a naphthyl or an anthracenyl group. Advantageously, it is a phenyl group.
The term “heteroaryl”, as used in the present invention, refers to an aromatic group comprising one or several, notably one or two, fused hydrocarbon cycles in which one or several, notably one to four, advantageously one or two, carbon atoms each have been replaced with heteroatoms selected from a sulfur atom, an oxygen atom and a nitrogen atom, preferably selected from an oxygen atom and a nitrogen atom. Preferably, the heteroaryl contains 5 to 12 carbon atoms, notably 5 to 10. It can be a furyl, thienyl, pyrrolyl, pyridyl, benzofuranyl, benzopyrrolyl, benzothipohenyl, isobenzofuranyl, isobenzopyrrolyl, isobenzothiophenyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, quinoxalyl or indyl.
In the context of the present invention, “unsaturated” means that the hydrocarbon chain may contain one or more unsaturation(s), i.e. a double bond C═C, advantageously one.
In the context of the present invention, an “optionally substituted group” is a group which is optionally substituted with one or more substituents selected in particular from:
Said substituent may also be a heteroaryl optionally substituted with one to three, preferably one or two C1-C4 alkyl, halogen or —OH.
Ra may also be a C1-C6 alkyl, optionally substituted with an aryl or a heteroaryl, said heteroaryl being optionally substituted with —OH. Preferably, in this case, Rb is H.
Preferably, an “optionally substituted group” is a group which is optionally substituted with one or more substituents selected in particular from:
The term “oxo” refers to the substituent of formula “C(═O)”.
The term “pharmaceutical composition” is meant in the framework of the present invention a composition having preventive and curative properties towards cancers.
Compounds of the present invention respond to the following formula (I):
According to a particular embodiment, compound of formula (I) comprises at least one lipophilic group. The term «lipophilic group» (or »hydrophobic group«) refers to a chemical group which confers lipophilic properties to the compound of formula (I). Such lipophilic properties enhance the bioavailability of the compound by favorizing the passage though biological boundaries such as cell membranes, plasma membranes or lysosome. In particular, the lipophilic group is represented by a hydrocarbon group such as an aliphatic chain, linear or branched, saturated or unsaturated, comprising at least 3 carbon atoms, a cycloalkyl or an aromatic ring. Preferably, the lipophilic group according to the present invention corresponds to a C2-C12 alkyne, in particular to C2-C6 alkyne and notably to a propynyl group.
According to preferred embodiments, X is selected in the group consisting of C1-C6 alkyl, O—C1-C6 alkyl, C(O), C(O)—C1-C6 alkyl and NH—C(O)—C1-C6 alkyl. In particular, X is a C1-C6 alkyl. Preferably X is a methyl, an ethyl or a n-propyl, more preferably an ethyl.
According to preferred embodiments, R4 is selected in the group consisting of H, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C7 cycloalkyl and aryl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH. In particular, R4 is selected in the group consisting of H, C1-C12 alkyl and aryl. Preferably, R4 is H.
In a particular embodiment, R3 is selected in the group consisting of H, optionally substituted C1-C24alkyl, optionally substituted C2-C24 alkenyl, optionally substituted C2-C24 alkynyl, optionally substituted C3-C7 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl.
In preferred embodiments, R1, R2 and optionally R3 are independently selected in the group consisting of H, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C7 cycloalkyl and aryl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH, provided that at least one of R1, R2 and R3 is not H. In particular, R1, R2 and optionally R3 are independently selected in the group consisting of H, C1-C12 alkyl, C2-C12 alkenyl and C2-C12 alkynyl, said alkyl, alkenyl or alkynyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH, provided that at least one of R1, R2 and R3 is not H. Preferably, R1, R2 and R3 are independently selected in the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl. In particular, R1, R2 and R3 are independently selected in the group consisting of H and C2-C6 alkynyl.
According to a particular embodiment, R1, R2 and optionally R3 are as defined above, provided that at least one of R1, R2 and R3 is an optionally substituted C2-C12 alkynyl, preferably a C2-C12 alkynyl optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH. More preferably, at least one of R1, R2 and R3 is C2-C6 alkynyl.
Preferably, when R1, R2 and/or R3 is an alkynyl, it is preferably an ethynyl, a propynyl or a butynyl, notably a propynyl group.
In a specific embodiment, X is —CH2CH2—, R4 is H, and R1 and R2 are independently selected in the group consisting of H, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C7 cycloalkyl and aryl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH, preferably R1 and R2 are independently selected in the group consisting of H, optionally substituted C1-C12 alkyl, C3-C7 cycloalkyl and C2-C6 alkynyl such as propynyl.
In another specific embodiment, X is —CH2CH2— and R1 and R4 are H, and R2 is H or a C2-C4 alkynyl such as a propynyl, advantageously H.
In particular embodiments, R1 and R2 are independently selected in the group consisting of H, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C7 cycloalkyl and aryl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH, provided that at least one of R1, R2 and R3 is not H. In particular, R1 and R2 are independently selected in the group consisting of H, C1-C12 alkyl, C2-C12 alkenyl and C2-C12 alkynyl, said alkyl, alkenyl or alkynyl being optionally substituted with one or more halogens, C1-C6 alkyl, aryl, oxo, NH2, CO2H or OH. Preferably, R1 and R2 are independently selected in the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl. In particular, R1 and R2 are independently selected in the group consisting of H and C2-C6 alkynyl. R1 and R2 are notably H.
Advantageously, R3 is selected from the group consisting of optionally substituted C1-C24alkyl, optionally substituted C2-C24 alkenyl, optionally substituted C2-C24 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl, optionally substituted —C(O)O—C1-C24alkyl, optionally substituted —C(O)O—C2-C24 alkenyl, optionally substituted —C(O)O—C2-C24 alkynyl, —C(O)O-optionally substituted aryl and optionally substituted —C(O)O-heteroaryl, optionally substituted —S(O)2—C1-C24alkyl, optionally substituted —S(O)2—C2-C24 alkenyl, optionally substituted —S(O)2—C2-C24 alkynyl, —S(O)2-optionally substituted aryl and optionally substituted —S(O)2-heteroaryl.
In a particular embodiment, R3 is selected from the group consisting of optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl, optionally substituted —C(O)O—C1-C12alkyl, optionally substituted —C(O)O—C2-C12 alkenyl, optionally substituted —C(O)O—C2-C6 alkynyl, —C(O)O-optionally substituted aryl and optionally substituted —C(O)O-heteroaryl, optionally substituted —S(O)2—C1-C12alkyl, optionally substituted —S(O)2-optionally substituted aryl and optionally substituted —S(O)2-heteroaryl.
R3 may in particular be selected from the group consisting of:
More specifically, R3 may be selected from the group consisting of:
According to a particular embodiment, R1 and R2 are independently selected in the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl, R3 is selected in the group consisting of C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl and advantageously at least one of R1, R2 and R3 is an optionally substituted C2-C12 alkynyl.
According to a preferred embodiment, the present invention relates to the following 10 compounds of formula (I):
According to another embodiment, the compound of formula (I) is:
The present invention also relates to a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, and at least one pharmaceutically acceptable excipient.
Contrary to serotonin, compounds of the present invention do not link serotonin receptors responsible for vasoconstriction and vasodilation properties, so that compounds of formula (I) are injectable.
The pharmaceutical compositions of the invention can thus be intended to oral or parenteral (e.g., subcutaneous, intramuscular, intravenous) administration, preferably intravenous administration. The active ingredient can be administered in unit forms for administration, mixed with conventional pharmaceutical carriers, to animals, preferably mammals including humans.
For oral administration, the pharmaceutical composition can be in a solid or liquid (solution or suspension) form.
A solid composition can be in the form of tablets, gelatin capsules, powders, granules and the like. In tablets, the active ingredient can be mixed with pharmaceutical vehicle(s) such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic and the like before being compressed. The tablets may be further coated, notably with sucrose or with other suitable materials, or they may be treated in such a way that they have a prolonged or delayed activity. In powders or granules, the active ingredient can be mixed or granulated with dispersing agents, wetting agents or suspending agents and with flavor correctors or sweeteners. In gelatin capsules, the active ingredient can be introduced into soft or hard gelatin capsules in the form of a powder or granules such as mentioned previously or in the form of a liquid composition such as mentioned below.
A liquid composition can contain the active ingredient together with a sweetener, a taste enhancer or a suitable coloring agent in a solvent such as water. The liquid composition can also be obtained by suspending or dissolving a powder or granules, as mentioned above, in a liquid such as water, juice, milk, etc. It can be for example a syrup or an elixir.
For parenteral administration, the composition can be in the form of an aqueous suspension or solution which may contain suspending agents and/or wetting agents. The composition is advantageously sterile. It can be in the form of an isotonic solution (in particular in comparison to blood).
The compounds of the invention can be used in a pharmaceutical composition at a dose ranging from 0.01 mg to 1,000 mg a day, administered in only one dose once a day or in several doses along the day, for example twice a day in equal doses. The daily administered dose is advantageously comprised between 5 mg and 500 mg, and more advantageously between 10 mg and 200 mg. However, it can be necessary to use doses out of these ranges, which could be noticed by the person skilled in the art.
The pharmaceutical compositions of the present invention may further comprise an additional therapeutic agent, notably useful in the treatment of iron-associated disorders, such as anemias. Preferably, this therapeutic agent is selected in the group consisting of Erythropoiesis-Stimulating Agents (ESAs) to activate the erythropoietin receptor and stimulate the bone marrow to make more red blood cells, such as Recombinant erythropoietin drugs as for example Luspatercept.
The compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, or the pharmaceutical composition according to the present invention are useful as a drug, notably in the prevention and/or treatment of iron-associated disorders.
The present invention thus relates to compound of formula (I) for use as a drug, in particular for use in the prevention and/or in the treatment of iron-associated disorders. The present invention also relates to a pharmaceutical composition according to the present invention for use as a drug, in particular for use in the prevention and/or in the treatment of iron-associated disorders.
The present invention also relates to the use of a compound of formula (I) according to the invention or a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition according to the present invention for the prevention and/or the treatment of iron-associated disorders.
The present invention also relates to a method for preventing and/or treating iron-associated disorders comprising the administration to a patient in need thereof of an effective dose of a compound of formula (I) according to the invention or a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition according to the present invention.
According to preferred embodiments, the iron overload-associated disorders are iron overload-associated disorders, notably selected among HFE-related hematochromatosis, non HFE-related hematochromatosis, congenital atransferrinenemia, iron-loading associated anemias, chronic liver diseases, chronic inflammation linked to cancer, autoimmune or inflammatory diseases, neurodegeneration with brain iron accumulation-associated diseases and polygenic neurodegenrative-associated diseases.
HFE-related hematochromatosis may notably be due to C282Y homozygosity or C282/H63D heterozygosity. Non HFE-related hematochromatosis include for example juvenile hemochromatosis type 2A or 2B, or may be due to Mutated transferrin receptor 2 or Mutated ferroportin 1 gene.
Neurodegeneration with brain iron accumulation-associated diseases include aceruloplasminemia, neuroferritinopathy, pantothenate kinase-associated neurodegenration, Wilson's disease and Beta-propeller Protein-Associated Neurodegeneration (BPAN).
Polygenic neurodegenerative disorders include Parkinson's disease and Alzheimer's disease.
In particular, the iron overload-associated disorder is iron-loading related anemia, such as thalassemia, myelodysplasy, aplastic anemia, Blackfan diamond anemia, congenital dyserythopoietic anemia, chronic hemoytic anemia, in particular sickel cell disease, hematopoietic stem-cell transplantation-related disorder and chronic liver disease including viral hepatitis, alcoholic hepatitis, steatohepatitis (NASH), dysmetabolic iron overload syndrome.
According to a specific embodiment, the iron-loading associated anemia is thalassemia, myelodysplasia or hematopoietic stem-cell transplantation-related disorder.
The compounds of the present invention may be prepared according to any method known by the skilled person in the art. In particular, they may be prepared by the following method.
A method for preparing a compound of formula (I) according to the present invention comprises the steps of:
A Rn group precursor (n being 1, 2 or 3) is understood, in the context of the present invention, as a compound able to react with deprotonated serotonin to insert a Rn group on the serotonin so as to obtain a compound of formula (I).
In a first embodiment, especially when R1, and/or R2, and/or R3 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, or an optionally substituted cycloalkyl, the method for preparing a compound of formula (I) may be described as a “nucleophilic substitution”.
Typically, this precursor comprises a Rn group attached to a leaving group such as a halide, in particular bromide or chloride, sulfonate esters, such as mesylate, tosylate or triflate.
In step (i), serotonin hydrochloride is typically dissolved in a solvent, notably an apolar aprotic solvent, including, but not limited to tetrahydrofuran (THF), diethylether (Et2O), dimethylether (DME), dichloromethane, hexane, 1-4-dioxane, toluene and chloroform, or a polar aprotic solvent such as acetonitrile, pyridine, acetone, DMSO or acetic anhydride.
According to particular embodiments, the base is Na2CO3, K2CO3, NaOH, KOH, Ca(OH)2, Ba(OH)2, NaH, KH or LiOH, in particular NaH.
In step (ii), when R1, R2 or R3 is H, serotonin does not react with the corresponding precursor of R1 group, R2 group or R3 group.
The reaction is typically conducted under inert atmosphere such as nitrogen (N2) or argon (Ar) atmosphere.
Optionally, additional steps of protection/deprotection and/or of functionalization well-known from the skilled person in the art may occur before step (i) to protect the position that should not react. For example, the primary amine of serotonin may be protected to enable selective transformation of the OH group into OR1 group.
The compound obtained can be separated from the reaction medium by methods well known to the person skilled in the art, such as by extraction, evaporation of the solvent or by precipitation or crystallisation (followed by filtration).
The compound can be also purified, if necessary, by methods well known to the person skilled in the art, such as by recrystallisation, by distillation, by chromatography on a column of silica gel or by high performance liquid chromatography (HPLC).
In a second embodiment, especially when R1, and/or R2, and/or R3 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, or an optionally substituted cycloalkyl, the method for preparing a compound of formula (I) may be described as a reductive amination sequence.
In this case, the Rn group is an aldehyde or a ketone.
In step (i), serotonin hydrochloride is typically dissolved in a solvent, notably an alcoholic solvent such as a C1-C6 alcohol. A “C1-C6 alcohol” refers to a straight or branched monovalent saturated hydrocarbon chain containing from x to y carbon atoms and substituted by at least one OH group. Examples of C1-C6 alcohols include, but are not limited to methanol, ethanol, isopropanol. Preferably, it is methanol.
According to particular embodiments, the base is an amine of formula N(C1-C6alkyl)3 or N(C1-C6alkyl)2(O—C1-C6alkyl), in particular triethylamine.
In this embodiment, the method further comprises a step (ii) of adding a hydride reductant suitable for reducing an imine or iminaldehyde to an amine, such as NaBH4 or NaBH3CN.
Optionally, additional steps of protection/deprotection and/or of functionalization well-known from the skilled person in the art may occur before step (i) to protect the position that should not react. For example, the primary amine of serotonin may be protected to enable selective transformation of the OH group into OR1 group.
In a third embodiment, especially when R1, and/or R2, and/or R3 is an optionally substituted —C(O)O—C1—C24alkyl, optionally substituted —C(O)O—C2-C24 alkenyl, optionally substituted —C(O)O—C2—C24 alkynyl, —C(O)O-optionally substituted aryl, optionally substituted —C(O)O-heteroaryl, the Rn group is a chloroformate, such as a optionally substituted C1—C24alkyl chloroformate, optionally substituted C2-C24 alkenyl chloroformate, optionally substituted C2-C24 alkynyl chloroformate, optionally substituted aryl chloroformate, optionally substituted heteroaryl chloroformate, respectively.
The other features are as described in the first embodiment of the method.
In a third embodiment, especially when R1, and/or R2, and/or R3 is an optionally substituted optionally substituted —S(O)2—C1-C24alkyl, optionally substituted —S(O)2—C2-C24 alkenyl, optionally substituted —S(O)2—C2-C24 alkynyl, —S(O)2-optionally substituted aryl and optionally substituted —S(O)2-heteroaryl, the Rn group is typically an optionally substituted C1-C24alkyl sulfonyl chloride, optionally substituted C2-C24 alkenyl sulfonyl chloride, optionally substituted C2-C24 alkynyl sulfonyl chloride, optionally substituted aryl sulfonyl chloride, optionally substituted heteroaryl sulfonyl chloride, respectively.
The other features are as described in the first embodiment of the method. Preferred base is a tri(C1-C6) alkylamine such as triethylamine, and preferred apolar aprotic solvent is dichloromethane.
All solvents and chemicals were purchased from commercially available sources and used without further purification, or purified according to Purification of Laboratory Chemicals (Armarego, W. L. F.; Chai, C. L. L. 5th Ed.). Solvents were dried under standard conditions. Reactions were monitored by thin layer chromatography (TLC) using pre-coated silica on aluminum plates from Merck (60F254). TLC plates were visualized with UV-light and/or by treatment with ceric ammonium molybdate solution (CAM) and heating. Products were purified on column chromatography with Silica gel 60 from Macherey Nagel (0.036-0.071 mm; 215-400 mesh), a CombiFlash Rf+ Teledyne Isco system fitted with pre-packed silica gel columns (Interchim) or/and preparative HPLC Quaternary Gradient 2545 equipped with a Photodiode Array detector (Waters) fitted with a reverse phase column (XBridge Prep C18 5 μm OBD, 30×150 mm).
NMR spectroscopy was performed on Bruker spectrometers. Spectra were run in DMSO-d6 or D2O or CD3OD, at 298 K. 1H NMR were recorded at 400 or 500 MHZ, and chemical shifts δ are expressed in ppm using the residual non-deuterated solvent signal as internal standard and the coupling constants J are specified in Hz. The following abbreviations are used: s, singlet; brs, broad singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets; dq, doublet of quartets; ddd, doublet of doublet of doublets; dqd, doublet of quartet of doublets; t, triplet; td, triplet of doublets; tdd, triplet of doublet of doublets; q, quartet; m, multiplet. We only reported labile protons that could be clearly identified in the spectra.
13C NMR were recorded at 101 or 126 MHZ, and chemical shifts δ are expressed in ppm using deuterated solvent signal as internal standard.
The purity of final compounds, determined to be >95% by UPLC MS, was recorded on a Waters Acquity H-class equipped with a Photodiode array detector and SQ Detector 2 with a reverse phase column (Aquity UPLC® BEH C18 1.7 μm, 2.1×50 mm). “Classic System”: ACN (+0.1% FA) and MilliQ Water (+0.1% FA): isocratic at 5% of ACN (0.2 min), then linear gradient from 5% to 100% of ACN in 2.3 min, then isocratic at 100% of ACN (0.5 min).
Column: Aquity UPLC® BEH C18 1.7 μm, 2.1×50 mm.
System: ACN (+0.1% FA) and MilliQ Water (+0.1% FA): isocratic at 5% of ACN (0.2 min), then linear gradient from 5% to 100% of ACN in 2.3 min, then isocratic at 100% of ACN (0.5 min).
ACN, acetonitrile; AcOH, glacial acetic acid; aq., aqueous; Boc2O, di-tert-butyl dicarbonate; DCM, dichloromethane; equiv., equivalent(s); ESI, electrospray ionization; EtOAc, ethyl acetate; EtOH, ethanol; Et2O, diethyl ether; Et3N, trimethylamine; FA, formic acid; HPLC, high pressure liquid chromatography; HRMS, high resolution mass spectroscopy; K2CO3, potassium carbonate; MeOH, methanol; MgSO4, sulfate magnesium; MS, mass spectrometry; NaH, sodium hydride; NMR, nuclear magnetic resonance; RT, room temperature; THF, TLC, thin-layer chromatography; UPLC, ultra-high performance liquid chromatography; UV, ultraviolet.
Procedure for the synthesis of A1, A3 and A4:
Under inert atmosphere, serotonin hydrochloride (100 mg, 0.470 mmol, 1 eq.) was dissolved in THF (5 mL). NaH (36 mg, 0.893 mmol, 1.9 eq.) was added to the mixture. The mixture is stirred for 30 min, then propargyl bromide (57 μL, 0.517 mmol, 1.1 eq.) was added. The mixture was stirred for 3.5 h, then was quenched with water. The resulting solution was extracted with DCM, dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (99/1 to 80/20) as eluent. 4 fractions were obtained and purified by preparative HPLC to give compounds A1, A3 and A4 after lyophilization.
Derivative A1 (N-(prop-2-yn-1-yl)-N-(2-(5-(prop-2-yn-1-yloxy)-1H-indol-3-yl) ethyl) prop-2-yn-1-amine):
UPLC: RT: 1.88
1H NMR (DMSO-d6, 500 MHZ): 10.65 (1H, s); 7.24 (1H, d, J 9.1 Hz); 7.11 (2H, d, J 18.3 Hz); 6.76 (1H, dd, J 8.75 & 1.75 Hz); 4.75 (2H, d, J 1.7 Hz); 3.50 (1H, bt); 3.46 (4H, bd); 3.17 (2H, bs); 2.76 (4H, bd, J 10.45 Hz). 13C NMR (DMSO-d6, 125 MHZ): 151.3; 132.3; 127.8; 123.9; 112.4 (2C); 112.0; 102.7; 80.5; 79.7 (2C); 78.1; 76.0 (2C); 56.6; 53.5; 42.0 (2C); 23.4.
Derivative A3 (Formic acid salt) (N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)prop-2-yn-1-aminium formate):
UPLC: RT: 0.80-1.00 1H NMR (DMSO-d6, 500 MHZ): 10.51 (1H, s); 8.31 (1H, s (FA)); 7.13 (1H, d, J 8.55 Hz); 7.05 (1H, s); 6.82 (1H, s); 6.60 (1H, dd, J 1.75 & 8.5 Hz); 3.50 (1H, d, J 1.65 Hz); 3.19 (1H, s); 2.91 (2H, t, J 7.15 Hz); 2.78 (2H, t, J 7.45 Hz).
13C NMR (DMSO-d6, 125 MHZ): 164.6; 150.6; 131.3; 128.3; 123.6; 112.1; 111.7; 111.2; 102.7; 81.7; 75.3; 48.5; 37.3; 24.9.
Derivative A4 (3-(2-(di(prop-2-yn-1-yl)amino)ethyl)-1H-indol-5-ol):
UPLC: RT : 1.42
1H NMR (DMSO-d6, 500 MHZ): 10.46 (1H, s); 8.58 (1H, bs (OH)); 7.11 (1H, d, J 8.5 Hz); 7.04 (1H, s); 6.82 (1H, s); 6.60 (1H, dd, J 1.1 & 8.4 Hz); 3.45 (4H, bs); 3.17 (2H, bs); 2.73 (4H, bs). (+FA trace)
13C NMR (DMSO-d6, 125 MHZ): 150.6; 131.2; 128.3; 123.4; 112.1; 111.7; 111.6; 102.7; 79.7 (2C); 76.1 (2C); 53.5; 42.0 (2C); 23.6. (+FA trace-163.9)
Serotonin hydrochloride (500 mg, 2.35 mmol, 1 eq.) was dissolved in water (9 mL). K2CO3 (665 mg, 4.81 mmol, 2.1 eq.) and BOC2O (538 mg, 2.46 mmol, 1.05 eq.) were added to the solution. The solution was stirred overnight, then extract with DCM. The organic phase was washed with HCl 5% and brine, then dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (100/0 to 90/10) as eluent to give the desired product (485 mg), which was engaged in the next step.
Under inert atmosphere, the product of the previous step (485 mg, 1.75 mmol, 1 eq.) was dissolved in dry acetonitrile (5 mL). K2CO3 (435 mg, 3.15 mmol, 1.8 eq.) and propargyl bromide (235 μL, 2.1 mmol, 1.2 eq.) were added to the solution. The mixture was stirred and heated at reflux overnight, cooled down to r.t. then filtered with acetonitrile and concentrated. The crude was purified by flash chromatography using cyclohexane/EtOAC (90/10 to 0/100) as eluent.
The product was then dissolved in 1M HCl in EtOAc (10 mL) and stirred for 2 h until the product was predominant in UPLC analysis. The mixture was then concentrated and the crude was directly purified by preparative HPLC to give the desired product after lyophilization.
Compound A2 (Formic acid salt) (2-(5-(prop-2-yn-1-yloxy)-1H-indol-3-yl)ethanaminium formate):
UPLC: RT: 1.57
1H NMR (DMSO-d6, 500 MHZ): 10.82 (1H, s); 8.45 (1H, s) 7.26 (1H, d, J 8 Hz); 7.18 (1H, d, J 2.1 Hz); 7.13 (1H, d, J 2.1 Hz); 6.78 (1H, dd, J 8.5 & 2.3 Hz); 4.77 (2H, d, J 1.8 Hz); 3.51 (1H, t, J 2.3 Hz); 2.94 (4H, m)
In the dark and under inert atmosphere, serotonin hydrochloride (200 mg, 0.940 mmol, 1 equiv.) was dissolved in THF (10 mL). NaH (45 mg, 1.128 mmol, 1.2 equiv.) was added to the mixture. The mixture is stirred for 30 min, then alkyl bromide (0.6 equiv.) was added. The mixture was stirred for 3.5 h, then was quenched with water. The resulting solution was extracted with DCM, dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (100/0 to 80/20) as eluent and by preparative HPLC to give the desired product after lyophilization. The obtained compound is the formic salt.
Yield: 44 mg, 21%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.44 in DCM/MeOH, 90/10. Strain green with CAM;
UPLC: RT: 0.8 to 1.0 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C13H15N2O+ 215.11; Found 215.22.
Yield: 43 mg, 19%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.5 in DCM/MeOH/Et3N, 95/5/2. Strain green with CAM;
1H NMR (CD3OD, 400 MHZ): □ ppm=7.16 (1H, d, J=8.4 Hz); 7.00 (1H, s,); 6.92 (1H, d, J=2.1 Hz); 6.67 (1H, dd, J=2.3 Hz, J=8.4 Hz); 5.21 (1H, m); 3.23 (2H, d, J=7.2 Hz); 2.89 (4H, s); 1.71 (3H, brs); 1.62 (3H, brs).
13C NMR (CD3OD, 101 MHZ): □ ppm=151.2; 136.8; 133.2; 129.3; 124.3; 122.3; 112.7; 112.5; 112.4; 103.5; 50.0; 47.4; 26.0; 25.9; 17.9.
UPLC: RT: 1.45 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C15H21N2O+ 245.16; Found 245.17.
Yield: 124 mg, 37%. Isolated as a orange powder, >95% pure by NMR and a single spot by TLC; Rf: 0.48 in DCM/MeOH, 90/10. Strain green with CAM;
1H NMR (DMSO-d6, 400 MHZ): □□ ppm=10.43 (1H, brs); 8.68 (1H, t, J=2.2 Hz); 8.60 (2H, d, J=2.1 Hz); 8.51 (1H, s); 7.08 (1H, d, J=8.5 Hz); 7.01 (1H, d, J=2.5 Hz); 6.74 (1H, d, J=2.2 Hz); 6.55 (1H, dd, J=2.3 Hz, J=8.6 Hz); 3.98 (2H, s); 2.77 (4H, m).
13C NMR (DMSO-d6, 101 MHZ): □ ppm=150.5; 148.4 (2C); 146.9; 131.3; 128.5 (2C); 128.3; 123.5; 117.2; 112.0; 111.8; 111.6; 102.6; 51.7; 49.6; 26.2.
UPLC: RT: 1.48 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C17H17N4O5+357.11; Found 357.13.
In the dark and under inert atmosphere, serotonin hydrochloride (500 mg, 2.35 mmol, 1 equiv.) was dissolved in THF (25 mL). NaH (188 mg, 2 equiv.) was added to the mixture. The mixture is stirred for 30 min, and then propargyl bromide (524 μL, 2 equiv.) was added. The mixture was stirred for 4 h, then was quenched with water. The resulting solution was extracted with DCM, dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (99/1 to 80/20) as eluent. 3 fractions were obtained and purified by preparative HPLC to give 3 products after lyophilization.
Yield: 5.5 mg, 0.8%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rr: 0.71 in DCM/MeOH, 95/5. Strain green with CAM;
Yield: 29 mg, 6%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.14 in DCM/MeOH, 95/5. Strain green with CAM;
Yield: 57 mg, 10%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rr: 0.43 in DCM/MeOH, 95/5. Strain green with CAM;
In the dark, serotonin hydrochloride (500 mg, 2.35 mmol, 1 equiv.) was dissolved in water (9 mL). K2CO3 (665 mg, 4.81 mmol, 2.1 equiv.) and BoczO (538 mg, 2.46 mmol, 1.05 equiv.) were added to the solution. The solution was stirred overnight, and then extracted with DCM. The organic phase was washed with aq. HCl 5% and brine, then dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (100/0 to 90/10) as eluent to give the desired product (485 mg), which was engaged in the next step.
In the dark and under inert atmosphere, the product of the previous step (138 mg, 0.5 mmol, 1 equiv.) was dissolved in dry acetonitrile (4 mL). K2CO3 (138 mg, 2 equiv.) and propargyl bromide (59 μL, 1.06 equiv.) were added to the solution. The mixture was stirred and heated at reflux overnight, cooled down to r.t. then filtered with acetonitrile and concentrated. The crude was purified by flash chromatography using cyclohexane/EtOAC (90/10 to 0/100) as eluent.
The product was then dissolved in CH2Cl2/TFA, 4/1 (4 mL) and stirred for 2 h until the product was predominant in UPLC analysis. The mixture was then concentrated and the crude was directly purified by preparative HPLC to give the desired product after lyophilization.
Yield: 53 mg, 49%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.38 in DCM/MeOH/Et3N, 90/10/2. Strain green with CAM
In the dark, serotonin hydrochloride (213 mg, 1 mmol) was dissolved in DCM/H2O, ½ (3.33/6.66 mL). Na2CO3 (223 mg, 2.1 mmol, 2.1 equiv.) was added to the mixture. The mixture is stirred for 30 min, and then alkylchloroformate (1 equiv.) was added. The mixture was stirred for 6 h, then was quenched with water. The resulting solution was extracted with DCM, dried on MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH (100/0 to 80/20) as eluent.
Yield: 217 mg, 84%. Isolated as a pale yellow oil, >95% pure by NMR and a single spot by TLC; Rf: 0.53 in DCM/MeOH, 98/2. Strain green with CAM;
1H NMR (CD3OD, 400 MHZ): □ ppm=7.15 (1H, d, J=8.6 Hz); 6.99 (1H, s,); 6.93 (1H, d, J=2.1 Hz); 6.66 (1H, dd, J=2.3 Hz, J=8.6 Hz); 4.64 (2H, d, J=2.4 Hz); 3.36 (2H, t, J=7.4 Hz); 2.85 (3H, m).
MS (ESI+) m/z [M+H]+ Calcd for C14H15N2O+ 259.10; Found 259.18.
Compounds LYS9 and LYS9a were obtained using the same protocol.
Yield: 217 mg, 84%. Isolated as a pale yellow oil, >95% pure by NMR and a single spot by TLC; Rf: 0.53 in DCM/MeOH, 98/2. Strain green with CAM;
1H NMR (CD3OD, 400 MHZ): d ppm=7.15 (1H, d, J=8.6 Hz); 6.99 (1H, s,); 6.93 (1H, d, J=2.1 Hz); 6.66 (1H, dd, J=2.3 Hz, J=8.6 Hz); 4.64 (2H, d, J=2.4 Hz); 3.36 (2H, t, J=7.4 Hz); 2.85 (3H, m).
13C NMR (CD3OD, 101 MHZ): d ppm=158.0; 151.1; 133.1; 129.4; 124.2; 112.6; 112.3 (2C); 103.5; 79.6; 75.6; 53.0; 42.7; 26.8.
UPLC: RT: 1.74 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C14H15N2O+ 259.10; Found 259.18.
Yield: 485 mg, 74%. Isolated as a light yellow powder, >95% pure by NMR and a single spot by TLC; Rf: 0.44 in DCM/MeOH, 90/10. Strain green with CAM;
1H NMR (CDCl3, 500 MHZ): δ ppm=7.94 (1H, brs); 7.24 (1H, d, J=8.6 Hz); 7.04 (2H, m); 6.81 (1H, dd, J=2.3 Hz, J=8.6 Hz); 5.04 (1H, brs); 4.67 (1H, brs); 3.46 (2H, m); 2.90 (2H, t, J=6.7 Hz); 1.46 (9H, s).
UPLC: RT: 1.99 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C15H21N2O3+277.15; Found 277.10.
In the dark, serotonin hydrochloride (200 mg, 0.94 mmol) was dissolved in DCM (9 mL). Triethylamine (210 μL, 1.5 mmol, 1.6 equiv.) was added to the mixture. The mixture is stirred for 30 min, and then methanesulfonyl chloride (43 μL, 0.56 mmol, 0.6 equiv.) was added slowly. The mixture was stirred for 18 h, then was quenched with water. The resulting solution was extracted with DCM, dried on MgSO4 and concentrated. The crude was purified by flash chromatography using n-Hexane/EtOAc (20/80 to 0/100) as eluent. Compound LYS11 is obtained as a white solid with 7% of yield (15 mg).
In the dark and under inert atmosphere, serotonin hydrochloride (213 mg, 1 mmol) was dissolved in dry MeOH (10 mL). Et3N (153 μL, 1.1 equiv.) was added to the mixture. The mixture was stirred for 30 min at RT, and then the corresponding ketone (1.1 eq.) was added. The mixture was stirred overnight, and after that time NaBH3CN (1.1 equiv.) was added. The reaction mixture was stirred further at RT for additional 60 minutes. Next, the solvent was evaporated under reduced pressure. The crude was taken in a mixture of Et2O/water, 1/1 (10/10 mL), the resulting solution was alkalinized with NaOH [2M] until to obtain pH=10, then extracted with Et2O (2×20 mL), then with DCM (1×20 mL). The organic phases were dried over MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH/Et3N (100/0/2 to 80/20/2) as eluent.
Yield: 39 mg, 17%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.68 in DCM/MeOH/Et3N, 90/10/2. Strain green with CAM; 1H NMR (CD3OD, 500 MHZ): □ ppm=8.55 (1H, s, (FA)); 7.19 (1H, d, J=8.7 Hz); 7.10 (1H, s,); 6.92 (1H, d, J=2.1 Hz); 6.70 (1H, dd, J=2.1 Hz, J=8.7 Hz); 3.73 (1H, quint;, J=8.1 Hz); 3.14 (2H, t, J=7.4 Hz); 3.04 (2H, t, J=7.4 Hz); 2.30 (2H, m); 2.17 (2H, m); 1.89 (2H, m).
UPLC: RT: 1.21 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C14H19N2O+ 231.14; Found 231.17.
Yield: 195 mg, 80%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.51 in DCM/MeOH/Et3N, 95/5/2. Strain green with CAM;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.53 (1H, s, (FA)); 7.19 (1H, d, J=8.6 Hz); 7.11 (1H, s,); 6.93 (1H, d, J=2.2 Hz); 6.70 (1H, dd, J=2.1 Hz, J=8.7 Hz); 3.55 (1H, quint., J=7.2 Hz); 3.25 (2H, t, J=7.5 Hz); 3.07 (2H, t, J=7.5 Hz); 2.10 (2H, m); 1.80 (2H, m); 1.64 (4H, m).
UPLC: RT: 1.34 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C15H21N2O+ 245.16; Found 245.10.
Yield: 253 mg, 98%. Isolated as a a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.53 in DCM/MeOH/Et3N, 95/5/2. Strain green with CAM;
1H NMR (CD3OD, 400 MHZ): □ ppm=7.16 (1H, d, J=8 Hz); 7.01 (1H, s,); 6.93 (1H, d, J=4 Hz); 6.67 (1H, dd, J=4 Hz, J=8 Hz); 2.90 (4H, m); 2.50 (1H, m); 1.90 (2H, m); 1.73 (2H, m); 1.63 (1H, m); 1.21 (5H, m).
UPLC: RT: 1.46 (classic system); MS (ESI+) m/z [M+H] +Calcd for C16H23N2O30 259.17; Found 259.24.
Yield: 120 mg, 44%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.43 in DCM/MeOH/Et3N, 95/5/2. Strain green with CMA; 1H NMR (CD3OD, 400 MHZ): □ ppm=7.17 (1H, d, J=8,6 Hz); 7.02 (1H, s,); 6.93 (1H, d, J=2.5 Hz); 6.67 (1H, dd, J=2.4 Hz, J=8.6 Hz); 2.91 (4H, m); 2.71 (1H, m); 1.89-1.80 (2H, m); 1.71-1.32 (10H, m). UPLC: RT: 1.57 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C17H25N2O+273.19;
Found 273.30.
Yield: 212 mg, 74%. Isolated as a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.6 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 400 MHZ): □□ ppm=7.17 (1H, d, J=8 Hz); 7.02 (1H, s,); 6.93 (1H, d, J=4 Hz); 6.67 (1H, dd, J=4 Hz, J=8 Hz); 2.94 (4H, m); 2.78 (1H, m); 1.73 (4H, m); 1.48 (10H, m).
UPLC: RT: 1.66 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C18H27N2O+ 287.20; Found 287.30.
Yield: 300 mg, 97%. Isolated as a a light grey powder, >95% pure by NMR and a single spot by TLC; Rf: 0.53 in DCM/MeOH/Et3N, 95/5/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.57 (1H, s, (FA)); 7.19 (1H, d, J=8.6 Hz); 7.12 (1H, s,); 6.93 (1H, d, J=2.2 Hz); 6.70 (1H, dd, J=2.2 Hz, J=8.6 Hz); 3.36 (1H, brs); 3.27 (2H, t, J=6.7 Hz); 3.12 (2H, t, J=6.7 Hz); 2.12 (2H, brs); 1.96 (2H, brd, J=13.6 Hz); 1.89 (4H, m); 1.78 (4H, m); 1.71 (2H, brd, J=13.6 Hz).
UPLC: RT: 1.62 (classic system); MS (ESI*) m/z [M+H]+ Calcd for C20H27N2O+ 311.21; Found 311.30.
Yield: 70 mg, 32%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rr: 0.29 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA; 1H NMR (CD3OD, 400 MHZ): □ ppm=7.18 (1H, d, J=8.6 Hz); 7.04 (1H, s,); 6.93 (1H, d, J=2.3 Hz); 6.68 (1H, dd, J=2.3 Hz, J=8.6 Hz); 3.05-2.91 (5H, m); 1.14 (6H, d, J=6.5 Hz).
UPLC: RT: 1.13 (classic system); MS (ESI*) m/z [M+H]+ Calcd for C13H19N2O+219.14; Found 219.21.
Yield: 57 mg, 23%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.63 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.57 (1H, s, (FA)); 7.19 (1H, d, J=8.6 Hz); 7.11 (1H, s,); 6.94 (1H, d, J=2.2 Hz); 6.71 (1H, dd, J=2.2 Hz, J=8.6 Hz); 3.24 (2H, m); 3.08 (2H, m); 3.04 (1H, quint., J=7.0 Hz); 1.71 (4H, m); 0.95 (6H, t, J=7.4 Hz). UPLC: RT: 1.40 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C15H23N2O+ 247.17; Found 247.20.
Yield: 131 mg, 35%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.33 in DCM/MeOH, 90/10. Strain green with CMA;
1H NMR (CD3OD, 400 MHZ): □ ppm=7.21-7.10 (7H, m); 7.01 (4H, m); 6.84 (1H, d, J=2.4 Hz); 7.07 (1H, s,); 6.94 (1H, d, J=2.4 Hz); 6.67 (1H, dd, J=2.4 Hz, J=8.6 Hz); 6.62 (1H, s); 3.04 (1H, p, J=6.9 Hz); 2.92 (2H, t, J=6.6 Hz); 2.78 (1H, t, J=6.6 Hz); 2.72 (2H, dd, J=6.9 Hz, J=13.8 Hz); 2.61 (2H, dd, J=6.6 Hz, J=13.8 Hz).
UPLC: RT: 1.91 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C25H27N2O+371.20; Found 371.27.
Yield: 131 mg, 35%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rr: 0.33 in DCM/MeOH, 90/10. Strain green with CMA; 1H NMR (CD3OD, 500 MHZ): □ ppm=8.54 (2H, s, (FA)); 7.20 (2H, d, J=8.6 Hz); 7.11 (2H, s); 6.92 (2H, d, J=2.3 Hz); 6.71 (2H, dd, J=2.3 Hz, J=8.6 Hz); 3.29-3.16 (6H, m); 3.07 (4H, m); 1.71 (2H, m); 1.48 (2H, m); 1.41-1.22 (14H, m).
UPLC: RT: 1.48 (classic system), MS (ESI+) m/z [M+H]+ Calcd for C30H42NAO2+ 491.33; Found 491.49.
In the dark and under inert atmosphere, serotonin hydrochloride (213 mg, 1 mmol) was dissolved in MeOH dry (10 mL) and the corresponding aldehyde (1.1 equiv.) was added. The mixture was stirred for 3 h, and after that time NaBH3CN (1.1 equiv.) was added. The reaction mixture was stirred further at RT for additional 30 minutes. Next, the solvent was evaporated under reduced pressure. The crude was taken in a mixture of Et2O/water, 1/1 (10/10 mL), the resulting solution was alkalinized with NaOH [2M] until to obtain pH=10, then extracted with Et2O (2×20 mL), then with DCM (1×20 mL). The organic phases were dried over MgSO4 and concentrated. The crude was purified by flash chromatography using DCM/MeOH/Et3N (100/0/2 to 80/20/2) as eluent.
Yield: 88 mg, 36%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.31 in DCM/MeOH/Et3N, 98/2/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.58 (1H, s, (FA)); 7.19 (1H, d, J=8.7 Hz); 7.09 (1H, s,); 6.95 (1H, d, J=2.2 Hz); 6.71 (1H, dd, J=2.2 Hz, J=8.7 Hz); 3.21 (2H, t, J=7.5 Hz); 3.07 (2H, t, J=7.5 Hz); 2.94 (2H, t, J=7.9 Hz); 1.65 (2H, quint, J=7.8 Hz); 1.33 (4H, m); 0.92 (3H, t, J=6.7 Hz).
UPLC: RT: 1.45 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C15H22N2O+ 247.17; Found 247.27.
Yield: 122 mg, 47%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.16 in DCM/MeOH/Et3N, 98/2/2. Strain green with CMA; 1H NMR (CD3OD, 400 MHz): □ ppm=7.16 (1H, d, J=8.7 Hz); 7.01 (1H, s,); 6.92 (1H, d, J=2.1 Hz); 6.67 (1H, dd, J=2.1 Hz, J=8.7 Hz); 2.91 (4H, s); 2.62 (2H, m); 1.48 (2H, m); 1.26 (6H, m); 0.88 (3H, t, J=6.5 Hz).
UPLC: RT: 1.68 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C16H25N2O+ 261.19; Found 261.19.
Yield: 10 mg, 4.5%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.3 in DCM/MeOH/Et3N, 80/20/2. Strain green with CMA;
1H NMR (CD3OD, 400 MHZ): □□ ppm=8.57 (1H, s, (FA)); 7.21 (1H, d, J=8.6 Hz); 7.13 (1H, s); 6.95 (1H, d, J=2.3 Hz); 6.72 (1H, dd, J=8.6Hz, J=2.3 Hz); 3.28 (2H, t, J=7.6 Hz); 3.10 (2H, t, J=7.6 Hz); 2.99 (2H, d, J=8.6 Hz). 1.72 (2H, d, J=7.5 Hz); 1.02 (3H, t, J=7.4 Hz).
UPLC: RT: 0.9 to 1.12 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C13H19N2O+ 219.14; Found 219.26.
Yield: 27.6 mg, 11.8%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.5 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.58 (s, 1H (FA)); 7.21 (1H, dd, J=8.7 Hz, J=2.7 Hz); 7.12 (1H, s); 6.96 (1H, d, J=2.4 Hz); 6.72 (1H, dd, J=8.6 Hz, J=2.0 Hz); 3.27 (2H, t, J=7.6 Hz,); 3.10 (2H, t, J=7.6 Hz); 3.00 (2H, t, J=8.2 Hz); 1.67 (2H, p, J=7.9 Hz); 1.42 (2H, h, J=7.4 Hz); 0.98 (3H, t, J=7.4 Hz).
UPLC: RT: 1.23 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C14H21N2O+ 233.16; Found 233.20.
Yield: 71.8 mg, 26%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.6 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.59 (1H, s, (FA)); 7.21 (1H, d, J=8.7 Hz); 7.12 (1H, s); 6.96 (1H, d, J=2.5 Hz); 6.72 (1H, dd, J=8.7 Hz, J=2.0 Hz); 3.26 (2H, dd, J=6.5 Hz, J=5.5 Hz); 3.09 (2H, t, J=7.6 Hz), 2.98 (2H, dd, J=6.6 Hz, J=5.3 Hz); 1.73-1.58 (2H, m); 1.44-1.25 (8H, m); 0.93 (3H, t, J=7.6 Hz).
UPLC: RT: 1.61 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C17H27N2O+ 275.20; Found 275.28.
Yield: 69 mg, 24%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rr: 0.4 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.60 (1H, d, J=2.3 Hz, (FA)); 7.21 (1H, d, J=8.6 Hz); 7.11 (1H, s); 6.97 (1H, d, J=2.4 Hz); 6.73 (1H, dd, J=8.6 Hz, J=2.3 Hz); 3.28-3.19 (2H, m); 3.08 (2H, t, J=7.6 Hz); 3.04-2.88 (2H, m); 1.75-1.60 (2H, m); 1.43-1.23 (10H, m); 0.92 (3H, t, J=6.7 Hz).
UPLC: RT: 1.85 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C18H29N2O+ 289.22; Found 289.22.
Yield: 22 mg, 7%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.7 in DCM/MeOH/Et3N, 80/20/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.59 (1H, s, (FA)); 7.21 (1H, d, J=8.6 Hz); 7.12 (1H, s); 6.96 (1H, d, J=2.3 Hz); 6.72 (1H, dd, J=8.6 Hz, J=2.3 Hz); 3.26 (2H, t, J=7.6 Hz); 3.09 (2H, t, J=7.6 Hz); 2.99 (2H, t, J=7.1 Hz); 1.67 (2H, p, J=7.4 Hz); 1.46-1.19 (14H, m); 0.92 (3H, t, J=6.8 Hz). UPLC: RT: 2.03 (classic system)
MS (ESI+) m/z [M+H]+ Calcd for C20H33N2O+ 317.25; Found 317.03.
Yield: 77 mg, 22%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.4 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA;
1H NMR (CD3OD, 500 MHZ): □ ppm=8.60 (1H, s, (FA)); 7.21 (1H, d, J=8.7 Hz); 7.12 (1H, s); 6.96 (1H, d, J=2.2 Hz); 6.72 (1H, dd, J=8.7 Hz, J=2.3 Hz); 3.25 (2H, t, J=7.6 Hz); 3.09 (2H, t, J=7.6 Hz); 2.97 (2H, t, J=8.0 Hz); 1.67 (2H, p, J=7.5 Hz); 1.47-1.21 (18H, m); 0.92 (3H, t, J=6.9 Hz).
UPLC: RT: 2.32 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C22H37N2O+ 345.28; Found 345.16.
Yield: 93 mg, 35%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.46 in DCM/MeOH/Et3N, 98/2/2.
1H NMR (CD3OD, 400 MHZ): □ ppm=7.31-7.21 (5 H, m); 7.16 (1H, d, J=8.6 Hz); 6.98 (1H, s); 6.90 (1H, d, J=2.4 Hz); 6.66 (1H, dd, J=8.6 Hz, J=2.4 Hz); 3.78 (2H, s); 2.91 (4H, s).
UPLC: RT: 1.48 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C17H19N2O+267.14; Found 267.21.
Yield: 154 mg, 49%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.10 in DCM/MeOH, 95/5.
1H NMR (CD3OD, 400 MHZ): □ ppm=7.16 (1H, d, J=8.8 Hz); 6.98 (1H, s); 6.89 (1H, d, J=2.4 Hz); 6.98 (1H, s); 6.76 (1H, brs); 6.71 (2H, brs); 6.66 (1H, dd, J=8.7 Hz, J=2.4 Hz); 5.90 (2H, s); 3.68 (2H, s); 2.89 (4H, brt, J=3.9 Hz).
UPLC: RT: 1.49 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C18H19N2O+ 311.13; Found 311.23.
Yield: 31 mg, 12%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf: 0.5 in DCM/MeOH/Et3N, 90/10/2. Strain green with CMA; 1H NMR (CD3OD, 500 MHZ): □ ppm=8.53 (1H, s); 7.63 (1H, d, J=1.8 Hz); 7.21 (1H, d, J=8.7 Hz); 7.11 (1H, s); 6.93 (1H, d, J=2.3 Hz); 6.72 (1H, dd, J=8.7 Hz, J=2.3 Hz); 6.61 (1H, d, J=3.3 Hz); 6.50 (1H, dd, J=3.3, 1.8 Hz); 4.27 (2H, s); 3.27 (2H, t, J=7.7 Hz); 3.09 (2H, t, J=7.6 Hz).
UPLC: RT: 1.22 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C15H17N2O+ 257.12; Found 257.14.
Yield: 37.3 mg, 13%. Isolated as a white amorphous solid, >95% pure by NMR and a single spot by TLC; Rf. 0.4 in DCM/MeOH/EtsN, 90/10/2. Strain green with CMA; 1H NMR (CD3OD, 400 MHZ): □ ppm=8.41 (1H, s); 7.09 (1H, d, J=8.6 Hz); 6.98 (1H, s); 6.81 (1H, d, J=2.2 Hz); 6.60 (1H, dd, J=8.7 Hz, J=2.3 Hz); 6.48 (1H, d, J=3.4 Hz); 6.22 (1H, d, J=3.3 Hz); 4.06 (2H, s), 3.12 (2H, t, J=7.6 Hz); 2.95 (2H, t, J=7.5 Hz). UPLC: RT: 1.43 (classic system); MS (ESI+) m/z [M+H]+ Calcd for C15H16N2O+ 291.08; Found 291.10.
In vivo studies have been carried out by using 3 mouse models.
Hbbth1/th1 mice carry a 3.7-kb homozygous spontaneous deletion that eliminates the Hemoglobin Subunit Beta (HBB) gene and 2 kb of the 5′ flanking region, including the promoter. On the basis of genetic and hematological criteria, these mice constitute the first animal model of beta-thalassemia. They exhibit iron overload in the spleen, transfusion independent, ineffective erythropoiesis, hepatosplenomegaly, anemia and aberrant erythrocyte morphology (see Dussiot et al., Nature Medicine 2014; 20 (4), 398-407).
This model is a peripheral serotonin deficient mice. It is a mouse model of low risk myelodysplastic syndrome, with ineffective erythropoiesis, light anemia, iron overload (spleen), abnormal red blood cells and apoptosis of proerythroblasts (see Côté et al., PNAS, 2003, 100 (23), 13525-13530).
Hepcidin, encoded by the HAMP gene, is the main regulator of iron homeostasis, and its expression is tightly regulated by signals including iron levels, erythropoietic activity, hypoxia, and inflammation.
It is a mouse model of hemochromatosis. Hepcidin deficient mice progressively develop multivisceral iron overload; plasma iron overcomes transferrin binding capacity, and nontransferrin-bound iron accumulates in various tissues including pancreas and heart (see Nicolas et al., PNAS 2001, 98 (15), 8780-8785).
Mouse models HbbTh1/Th1 with ineffective erythropoiesis and iron overload received intraperitoneal (Ip) injection of A1 or A3 derivatives starting on day 0.
Mouse models Tph1 KO with ineffective erythropoiesis and iron overload received intraperitoneal (Ip) injection of A1, A3, A4 derivatives or serotonin starting on day 0.
Mouse model of iron overload without ineffective erythropoiesis (Hamp KO) received intraperitoneal (Ip) injection of A3 derivatives or serotonin starting on day 0.
Control mice (Wild-type, non-modified, healthy) and a model mice of each type who did not receive any injection were also evaluated.
In a first round of experiments, a complete red blood cells count (RBC) was achieved on day 1, day 2 and day 5.
On day 5, the animals were sacrificed and histology of their organs and iron measurement in organs was carried out.
In a second round of experiments, a complete red blood cells count (RBC) was achieved on day 2 day 5, day 10, day 15, day 20, day 25 and day 30. 4 mice were sacrificed on day 5 and every 5 days afterward for toxicity tests, Flow Cytometry Analysis and FACS (fluorescence-activated single cell sorting) essentially on bone marrow and spleen, biochemical analysis, iron status (organs, serum and urines), and histology.
The evolution over days of the red blood count (RBC), the hemoglobin rate and the hematocrit contents in HbbTh1/th1 mice that received either derivative A1 or derivative A3 is illustrated in
It is demonstrated that derivatives A1 and A3 improved hemoglobin (
The iron content in different organs (spleen, bone marrow) has been measured on day 5 (after sacrifice) in control mice, and in HbbTh1/th1 mices that received A1 or A3. The results are illustrated in
These results show that derivatives A1 or A3 decreased the iron overload in spleen, of HbbTh1/th1 mices. The iron is mobilized out of the spleen and relocate into cells of the bone marrow where it is needed for the synthesis of red blood cells.
Second round experiment
Results of FACS analysis and RBC obtained for a HbbTh1/th1 mice that received derivative A3, compared to control mice treated with PBS (phosphate buffer saline), are reported in
Intraperitoneal injection of 20 mg/g of derivative A3 for 13 and 21 days respectively improved condition of the mice compared with control, which in contrast exhibited Ineffective Erythropoiesis (IE) characterized by anemia with expansion of immature erythroblasts, resulting in an imbalanced ratio of immature/mature erythroblasts as observed in humans.
ProE and Ebaso are part of phases I-II, EBaso and LBaso are part of phases III-IVa, Poly and Ortho are part of phases IVb-V of cells differentiation. The mature stage is also called “acido”.
Flow cytometry analyses of bone marrow cells from A3-treated HbbTh1/th1 mice revealed a decrease in both the percentage Ter-119+CD71+FSC cells (III-IVa) and a concomitant increase in the percentage and the absolute number of Ter-119+CD71−FSC cells (IVb-V) compared to in PBS-treated mice. It may thus be concluded that Compound A3 corrects pathological features of β-thalassemia in this mouse model.
Following 13 days of in vivo injection of compound A3: correction of bone marrow expansion in β-thalassemia Hbbth1/th1 mice is observed (see
Addition of 5-HT derivatives restore the ratio immature/mature erythroblasts (Ratio IV/V). Following 13 days of in vivo injection of compound A3, a decrease in iron overload in β-thalassemia Hbbth1/th1 mice id observed (see
A significant increase of urinary ferritin levels is observed for mice treated with A3 compared to the control mice (see
It may be concluded from these tests that erythroid expansion and maturation arrest, together with reduced cell survival is observed in HbbTh1/Th1 mice treated with PBS (control mice).
In HbbTh1/Th1 mice treated with compound A3, in contrast, erythroid expansion is restored and maturation arrest is stopped, while cell survival is increased.
Compound A3 thus acts as an iron shuttle.
Erythropoiesis and iron metabolism are closely linked. Erythropoiesis, the fine-tuned process by which red blood cells (RBCs) are produced in the bone marrow, depends on oxygen and iron availability for proper hemoglobin (Hb) synthesis. In B-thalassemic patients, the reduced life span of RBCs leads to increased proliferation and decreased differentiation of erythroid precursors (ineffective erythropoiesis) in bone marrow and extramedullary erythropoiesis in the spleen. This ineffective erythropoiesis (IE) further contributes to anemia and causes iron overabsorption to meet the increased iron demand for Hb synthesis, leading to organ iron overload. Hence patients suffer the complications of both iron overload and chronic anemia. In view of the above, the compounds of the invention thus offer a promising innovative treatment for normalizing iron stores and restoring erythropoiesis in thalassemic patients.
Model 2 (Tph1 KO mice): red blood cells production and iron overload
The evolution over days of the red blood count, the hemoglobin rate, the hematocrit contents, the mean cellular volume (MCV) in Tph1 KO mice that received either derivative A3 or derivative A4 or serotonin is illustrated on
It is demonstrated that, derivatives A3 and A4 and serotonin improved hemoglobin (
MCV is a measure of the average volume (size) of red blood cells (RBCs) in a blood sample and an increase in MCV is associated with macrocytic anemia. The results suggest that injection of A3, A4 derivatives or serotonin ameliorate the anemic phenotype. In addition, the iron content in different organs (spleen, bone marrow) has been measured on day 5 (after sacrifice) in control mice, and in Tph1 KO mice that received A3 or A4 derivatives or serotonin. The results are illustrated in
Second round experiment
Intraperitoneal (IP) injection of 20 mg/g of derivative A3 for 5 and 21 days respectively improved condition of the mice compared with controls, which in contrast exhibited myelodisplasic syndrome-like phenotypes.
The iron content in each the body, the plasma, the duodenum, the liver, the spleen, the bone marrow, the kidney and the pancreas in a Tph1 KO mice and in wild type mice (WT) is reported in
Following 5 days of treatment, compound A3 corrects cellular iron misdistribution in Tph1 KO mice, compared to non-treated Tph1 KO mice (see
Following 21 of IP injection, compound A3 corrects cellular iron misdistribution in Tph1 KO mice, compared to Tph1 KO mice treated with PBS (see
Reduced erythroid expansion together with reduced cell survival is observed in 5-HT deficient mice (Tph1 KO) mice treated with PBS.
In contrast, in 5-HT deficient mice treated with compound A3, erythroid expansion is restored and cell blood survival is increased.
Compound A3 acts as an iron shuttle, thus offering a promising innovative treatment for normalizing iron stores and restoring erythropoiesis in myelodisplasic syndrome (MDS) patients.
Model 3 (Hamp KO): iron overload
The iron content was measured in blood and liver in Hamp KO mice and control mice on day 5 (after sacrifice) that received A3 or serotonin. The results are illustrated in
Mounting evidence from a number of investigators suggests that manipulation of the serotonergic system for the coordination of iron homeostasis with erythropoiesis could counter the vicious cycle of ineffective erythropoiesis and iron overload seen, for example, in patients with myelodysplastic syndromes (MDS).
Analysis of Tph1-knockout mice (Model 2) revealed a key function of 5-HT in erythropoiesis: the mice present a phenotype of macrocytic anemia due to ineffective erythropoiesis and reduced red blood cells (RBCs) survival. Further investigation of the 5-HT-deficient mice made clear that, in bone marrow (BM), 5-HT plays a cell-autonomous role in erythroblasts and is required for normal proliferation of CD36+ human cord blood cells. Our data has shown that impaired erythroid proliferation capacities seen in MDS patients were associated with reduced 5-HT levels, providing evidence that the lack of 5-HT contributes to the emergence of the disease.
Moreover, using in vivo models of MDS-related anemia (Model 2—Tph1 KO mice), we showed that pharmacological modulation of 5-HT levels rescued the anemic phenotype (see above).
In vitro tests were carried out on cells derived from blood of β-thalassemic patients before transfusion
First the mechanism of action of 5-HT derivatives seen in cells from mice models was confirmed in human progenitors' erythroid cells from thalassemic patients (see FIGS. 8A and 8B, Ctrl=Control patients, B-Thal=thalassemic patients). More specifically, a significant decrease in 5-HT level in blood from MDS patients (n=15) as compared to control individuals (n=14) is observed.
It was further demonstrated that patients who had refractory anemia with ring sideroblasts—or RARS, an MDS phenotype—presented lower 5-HT levels in the serum pointing to a role for 5-HT in iron homeostasis (
Finally, in cells from beta-thalassemic patients (n=3), it was demonstrated that compound A3 increases differentiation of erythroid progenitors as revealed by the decrease in immature/mature ratio (see
Further tests were carried out on skin fibroblasts from Friedreich ataxia and Beta-propeller protein-associated neurodegeneration (BPAN) patients, to assess in particular the effects of the compounds of the invention on iron accumulation in both the cytosol and mitochondria of said fibroblasts.
Cultured skin fibroblasts from Friedreich ataxia patients were used as described in Petit et al., Blood. 2021; 137 (15): 2090-2102 and Ingrassia et al., Front Genet 2017 Feb. 17; 8:18.
Western blot analysis of skin fibroblasts from FA/BPAN patients treated with 100 uM ferric ammonium citrate (FAC) or placebo +/−A3 are shown in
Western blot analysis of skin fibroblasts from FA/BPAN patients treated with 100 uM ferric ammonium citrate (FAC) or placebo +/−A3 are shown in
In condition of iron overload (FAC 100 uM), addition of A3, increased p62 expression (˜60%) suggesting an increase in autophagic flux.
Western blot analysis of skin fibroblasts from FA/BPAN patients treated with 100 uM ferric ammonium citrate (FAC) or placebo +/−derivatives according to the present invention are shown in
Compound B1 corresponds to the derivative LYS12 as described above. Compound B2 corresponds to the derivative LYS29 as described above. Compound B3 corresponds to the derivative LYS9 as described above. Compound B4 corresponds to the derivative LYS9a as described above.
4. Conclusion
The compounds of the invention, and in particular compound A1, A3 and A4, tested in vivo, in vitro, in human cells and in animal models of thalassemia and MDS have three key properties—namely:
| Number | Date | Country | Kind |
|---|---|---|---|
| 21306124.5 | Aug 2021 | EP | regional |
The present application is a filing under 35 U.S.C. 371 as the National Stage of International Application No. PCT/EP2022/073004, filed Aug. 17, 2022, entitled “NOVEL SEROTONIN DERIVATIVES AND THEIR USES FOR TREATING IRON-ASSOCIATED DISORDERS,” which claims priority to European Application No. 21306124.5 filed with the European Patent Office on Aug. 17, 2021, both of which are incorporated herein by reference in their entirety for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/073004 | 8/17/2022 | WO |
